Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

pregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanom

Full text
Diogenes Siena, Adamo Davi [1, 2] ; de Barros, Isabela Ichihara [1, 2] ; Storti, Camila Baldin [1, 2] ; Oliveira de Biagi Junior, Carlos Alberto [1, 2] ; da Costa Carvalho, Larissa Anastacio [3] ; Maria-Engler, Silvya Stuchi [3] ; Sousa, Josane de Freitas [4] ; Silva Jr, Wilson Araujo
Total Authors: 8
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Ribeirao Preto - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Ctr Cell Based Therapy, Ribeirao Preto - Brazil
[3] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil
[4] Fed Univ Para UFPA, Inst Biol Sci, Belem, Para - Brazil
Total Affiliations: 4
Document type: Journal article
Source: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE; v. 26, n. 3, p. 671-683, FEB 2022.
Web of Science Citations: 1

Our previous work using a melanoma progression model composed of melanocytic cells (melanocytes, primary and metastatic melanoma samples) demonstrated various deregulated genes, including a few known lncRNAs. Further analysis was conducted to discover novel lncRNAs associated with melanoma, and candidates were prioritized for their potential association with invasiveness or other metastasis-related processes. In this sense, we found the intergenic lncRNA U73166 (ENSG00000230454) and decided to explore its effects in melanoma. For that, we silenced the lncRNA U73166 expression using shRNAs in a melanoma cell line. Next, we experimentally investigated its functions and found that migration and invasion had significantly decreased in knockdown cells, indicating an essential association of lncRNA U73166 for cancer processes. Additionally, using naive and vemurafenib-resistant cell lines and data from a patient before and after resistance, we found that vemurafenib-resistant samples had a higher expression of lncRNA U73166. Also, we retrieved data from the literature that indicates lncRNA U73166 may act as a mediator of RNA processing and cell invasion, probably inducing a more aggressive phenotype. Therefore, our results suggest a relevant role of lncRNA U73166 in metastasis development. We also pointed herein the lncRNA U73166 as a new possible biomarker or target to help overcome clinical vemurafenib resistance. (AU)

FAPESP's process: 18/04017-9 - Genomic and functional characterization of putative melanoma-restricted lncRNAs (RMELs)
Grantee:Enilza Maria Espreafico
Support Opportunities: Regular Research Grants
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 18/14936-1 - Mitochondrial metabolism dictates the heterogeneity and resistance of melanoma
Grantee:Larissa Anastacio da Costa Carvalho
Support Opportunities: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 17/04926-6 - Melanoma and chemoresistance: in vitro and in silico models to exploit therapeutic targets
Grantee:Silvya Stuchi Maria-Engler
Support Opportunities: Research Projects - Thematic Grants